Tag Archives: tax reform
Dear Research Advocate:
Last week, I wrote about the international trade deficit our country faces. This week, I’d like to focus on the budget deficit. From 2003 to 2011, Medicare and Medicaid spending grew 74% while our economy only grew 35%. With that kind of differential, no government can balance its budget. We need research to address disabling and costly illnesses, but that won’t be enough in and of itself to bridge the gap. We also need tax and entitlement reform that preserves needed services, squeezes out waste and inefficiency (by the way, that’s why we must also fight to protect health economics research, health services research and other research that optimizes health care financing and delivery) and promotes pro-innovation tax changes that are designed to sustain a prosperous nation.
One vocal advocate for a long-term view of the steps our nation must take to secure human and economic progress, including committing to ample and stable public support for medical research, is The Honorable John Porter, Research!America chair and former U.S. representative. He recently penned an op-ed published on CNN.com and elsewhere titled “A do-nothing Congress isn’t healthy.” Mr. Porter makes it clear that we must “view research through the prism of future generations” to properly set a legislative course towards prosperity and good health, and we must not delay. Continue reading →
Dear Research Advocate,
With all the conversation about the debt ceiling and tax and entitlement reform, it may surprise you to know that an additional topic is on many minds. A wide majority of Americans, 72%, say the new Congress and the president should take action to expand medical research within the first 100 days of the new legislative session. See this and more in America Speaks, Volume 13, a compilation of national poll data providing insights into public sentiment on key research-related issues. See our press release and download the full Poll Data Summary. These polling results are designed to be used in your advocacy and outreach!
Among the growing number of issues that need to be resolved by the new Congress is the medical device tax, which could send research jobs overseas and shrink a critical segment of our innovation economy. In The Hill, Rep. Bob Latta (R-OH) writes about the consequences the tax could have on the medical device industry, including the possibility of a massive decline in R&D investment. As our economy recovers, policy makers must better incentivize R&D investment to keep our nation competitive and ensure that companies are continuing to invest in life-saving research.
More on the first 100 days: As you know, the sequestration deadline has been moved two months, with another delay possible, and there is talk of other cuts to discretionary spending. The delay is terribly frustrating for those planning research investment and sends a very negative message to young scientists planning a career, but it does buy us more time to make our case. The Washington Post published an op-ed by three Washington, DC, institutional members of Research!America that argues compellingly for such funding. Take action now and do two things — collaborate with your local colleagues to write an op-ed for a local publication and send an email to your representatives. Tailor the alert we provide to let them know how cuts could affect your institution and your community.
For those of you in Georgia, the appointment of Rep. Jack Kingston (R-GA) as chairman of the committee that allocates most of the federal funding for biomedical and health research funding presents an important advocacy opportunity. Research!America is helping to facilitate collective action by Georgia institutions, and we would welcome your participation. Please contact Max Bronstein, director of science policy, if you haven’t heard from us yet! Recently, I had the opportunity to discuss Rep. Kingston’s record and prospects for the 113th Congress with Randy Barrett of the ScienceInsider.
Great news! The U.S. Supreme Court issued a decision on behalf of patients and stem cell researchers, effectively bringing to a close the infamous Sherley v. Sebelius case that threatened federal funding for embryonic stem cell research. This decision marks a major victory for the stem cell research cause, but it is critical that all of us remain vigilant; actions at the state level could still curtail embryonic stem cell research. View our press statement on the decision and our updated resource page on stem cell research. We will be talking about the importance of stem cell research when we honor the California Institute for Regenerative Medicine (CIRM) at our upcoming Advocacy Awards dinner. See more about this March 13, 2013, event here.